论文部分内容阅读
华盛顿消息:据研究人员报告,使用放射性抗体攻击癌细胞,治疗原发性肝癌取得初步疗效,使一些癌症患者的平均缓解期延长了三倍,并使一些癌肿明显缩小。这种新技术可能对治疗何杰金氏病有效,对其他几种癌症,如白血病、乳腺癌、肺癌及可疑的AIDS也适用。研究人员介绍简况时说,自1979年以来,共观察了104例肝癌病例,近一半的病人症状有所缓解,有71%的病人得到完全缓解。肝癌病人一般缓解率为15%,并且病人在开始治疗后的平均存活期限仅有3～4个月。领导加利福尼亚大学(旧金山)和阿尔伯特·爱因斯坦(费城)医学中心研究小组的放射性肿瘤学教授(约翰斯·霍普金斯大学)StanleyE Order说:“在接受放射
Washington news: According to researchers, using radioactive antibodies to attack cancer cells has achieved initial efficacy in the treatment of primary liver cancer, which has tripled the average remission period for some cancer patients and has caused some cancers to shrink significantly. This new technology may be effective for the treatment of Hodgkin’s disease and also for other types of cancers such as leukemia, breast cancer, lung cancer and suspicious AIDS. The researchers introduced the briefing and said that since 1979, a total of 104 cases of liver cancer have been observed. Nearly half of the patients have their symptoms relieved, and 71% of patients have achieved complete remission. The general response rate of liver cancer patients is 15%, and the average survival period of patients after starting treatment is only 3 to 4 months. Professor Stanley E Order, a professor of radiological oncology (Johns Hopkins University) led by the University of California (San Francisco) and Albert Einstein (Philadelphia) Medical Center Research Group, said: "In accepting radiation